98%
921
2 minutes
20
The potential of three-dimensional (3D) printing as an approach for developing advanced, patient-specific, highly accurate, and customizable materials has captured the interest of the pharmaceutical and biomedical sciences sectors. The rheological and biodegradation characteristics of xanthan gum in 3D printed formulations make them an excellent platform technology for drug administration and biological applications, according to research. Applications for 3D printing platforms include transdermal, implantable, ophthalmic, and drug delivery. XG offers a prolonged and controlled release mechanism in the formulations for the administration of drugs. Additionally, it may generate hydrogels, matrix-type systems, and bioadhesive systems, which improve encapsulation efficiency, alter release kinetics, and increase bioavailability. It is a great material to use to make both soft and hard tissues because XG can produce chemically and physically crosslinked hydrogel, which enhances drug delivery and mechanical stability. Research is also being done on XG-based bioinks for 3D printing, which may prove useful for wound healing, bone regeneration, and cartilage repair. In this review, we attempted to evaluate the potential of XG in 3D printing for pharmaceutical and biological applications. The physicochemical and rheological properties of 3D printing are specifically examined, along with the many applications in tissue engineering and drugs delivery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.carbpol.2025.123914 | DOI Listing |
J Drug Target
September 2025
Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Background: Chronic constriction injury (CCI) of the sciatic nerve induces neuropathic pain, inflammation, oxidative stress, and neurodegenerative changes, impairing sensory and emotional function. While curcumin is well recognized for its anti-inflammatory and neuroprotective properties, its therapeutic use is limited by poor bioavailability. Curcumin liposomal nanoparticles (CLNs) offer improved delivery and stability.
View Article and Find Full Text PDFPharm Dev Technol
September 2025
School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, wenhua Road 103, Shenyang 110016, PR China.
Nimodipine (NMP), a poorly water-soluble small-molecule agent, demonstrates notable therapeutic limitations in addressing cerebral vasospasm secondary to subarachnoid hemorrhage (SAH). Owing to its inherent physicochemical properties characterized by low oral bioavailability, rapid elimination half-life, and extensive first-pass metabolism, conventional formulations necessitate frequent dosing regimens to sustain therapeutic plasma concentrations. These pharmacological challenges collectively result in suboptimal patient adherence, marked plasma concentration fluctuations, and recurrent vascular irritation.
View Article and Find Full Text PDFACS Appl Mater Interfaces
September 2025
Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Kraków 30-387, Poland.
The multifunctional systems presented here introduce an innovative and deeply thought-out approach to the more effective and safer use of temozolomide (TMZ) in treating glioma. The developed hydrogel-based flakes were designed to address the issues of local GBL therapy, bacterial neuroinfections, and the bleeding control needed during tumor resection. The materials obtained comprise TMZ and vancomycin (VANC) loaded into cyclodextrin/polymeric capsules and embedded into gelatin/hyaluronic acid/chitosan-based hydrogel films cross-linked with genipin.
View Article and Find Full Text PDFMed Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDF